SAN DIEGO, Dec. 2 /PRNewswire/ -- BrainCells Inc. (BCI), a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, announced today the appointment of David E. Thompson to its board of directors. Thompson is a veteran of the pharmaceutical industry, with a 30-year tenure at Eli Lilly and Co. where he focused on building the company while leading corporate strategy, business development, corporate ventures and alliance management.
"Dave is an industry veteran with broad experience and numerous relationships in the pharmaceutical and biotech world," said Jim Schoeneck, BrainCells CEO. "He will be a valuable resource as we execute corporate strategy and potential transactions around our neurogenesis platform technology and compounds in clinical development, including BCI-540, for which we anticipate Phase II data for the treatment of depression and anxiety in 2009."
Thompson conducted a successful 30-year career at Eli Lilly and its
affiliates which culminated in a position as vice president of corporate
strategy and business development. During his tenure at Eli Lilly, Thompson
focused his expertise on all aspects of Lilly's business, holding numerous
positions including director of corporate new product planning and licensing,
president and general manager of Eli Lilly Canada, president/CEO of IVAC
Corporation and vice president of pharmaceutical product management and
licensing. Currently, Thompson is executive chairman of Bayhill Therapeutics,
Inc. and is a member of the board of directors for Anthera Pharmaceuticals,
Inc. Born in Lansing, Michigan, he is a graduate of
"BCI's scientific application of neurogenesis for the treatment of mood
disorders and other CNS diseases has the potential to revolutionize th
|SOURCE BrainCells Inc.|
Copyright©2008 PR Newswire.
All rights reserved